Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$35.80M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$38.51M

FY 2025 · Annual

-61.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Depreciation & Amortization108.98K113.33K8K00
Deferred Income Tax00000
Stock-Based Compensation00191K1.13M0
Change in Working Capital(610.09K)(1.45M)1.58M1.64M(2.36M)
Accounts Receivables(22.5K)0(306K)58K0
Inventory00000
Accounts Payables0(344.95K)1.65M1.06M2.88M
Other Working Capital(587.59K)(1.1M)237K523K(5.25M)
Other Non-Cash Items22.12M366.86K25K23K19.16M
Operating Cash Flow(10.86M)(12.01M)(5.9M)(14.81M)(35.8M)
Capital Expenditures(5.25K)(2.33K)000
Acquisitions (Net)00000
Purchases of Investments(345.54K)0000
Sales of Investments803.4K0000
Other Investing Activities003K00
Investing Cash Flow452.61K(2.32K)3K00
Debt Repayment0624.3K(624K)(501K)0
Common Stock Issued9.19M7.93M14.19M100.37M38.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities544.65K0000
Financing Cash Flow9.74M8.55M13.57M99.87M38.51M
Effect of Forex Changes00000
Net Change in Cash(666.32K)(3.46M)7.67M85.06M2.71M
Free Cash Flow(10.86M)(12.02M)(5.9M)(14.81M)(35.8M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$52.6M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$2.4M
+ Other Non-Cash$19.2M
= Operating Cash Flow-$35.8M
- Capex$0
= Free Cash Flow-$35.8M

Analysis

FY2025 free cash flow is -$35.8M. FCF conversion is 68.1% of net income. Operating cash flow was -$35.8M, with capex of $0. The largest bridge item is Other Non-Cash at $19.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipSep 17, 2026
4Statement of changes in beneficial ownershipSep 15, 2026
4Statement of changes in beneficial ownershipSep 15, 2026
SC 13G/ASC 13G/A filingSep 11, 2026
8-KCurrent reportSep 9, 2026

Does TENX generate free cash flow?

Tenax Therapeutics, Inc. (TENX) generated -$35.80M of free cash flow in fiscal 2025.

How much operating cash flow does TENX produce?

Operating cash flow was -$35.80M, before capital expenditures of $0.00.